FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113686775> ?p ?o ?g. }

• W2113686775 endingPage "1566" @default.
• W2113686775 startingPage "1557" @default.
• W2113686775 abstract "Abstract Purpose: We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC). Experimental Design: Patients with histologically confirmed measurable advanced HCC and adequate hematologic, hepatic, and renal functions received cediranib 30-mg orally once daily (4 weeks/cycle). The primary endpoint was progression-free survival (PFS) rate at 3 months. Other endpoints included response rates, overall survival (OS), pharmacokinetics (PK), and biomarkers for cediranib. Results: Cediranib treatment resulted in an estimated 3-month PFS rate of 77% (60%, 99%). Median PFS was 5.3 (3.5,9.7) months, stable disease was seen in 5/17 patients (29%), and median OS was 11.7 (7.5–13.6) months. Grade 3 toxicities included hypertension (29%), hyponatremia (29%), and hyperbilirubinemia (18%). Cediranib PK were comparable to those seen in cancer patients with normal hepatic function. Plasma levels of VEGF and PlGF increased and sVEGFR1, sVEGFR2, and Ang-2 decreased after cediranib treatment. PFS was inversely correlated with baseline levels of VEGF, sVEGFR2, and bFGF and with on-treatment levels of bFGF and IGF-1, and directly associated with on-treatment levels of IFN-γ. OS was inversely correlated with baseline levels of sVEGFR1, Ang-2, TNF-α, CAIX, and CD34+CD133+CD45dim circulating progenitor cells and on-treatment levels of sVEGFR2. Conclusions: Despite the limitations of primary endpoint selection, cediranib at 30-mg daily showed a high incidence of toxicity and preliminary evidence of antitumor activity in advanced HCC. Hepatic dysfunction did not seem to affect the steady-state PK of cediranib. Exploratory studies suggested proangiogenic and inflammatory factors as potential biomarkers of anti-VEGF therapy in HCC. Clin Cancer Res; 19(6); 1557–66. ©2013 AACR." @default.
• W2113686775 created "2016-06-24" @default.
• W2113686775 creator A5008468404 @default.
• W2113686775 creator A5013091949 @default.
• W2113686775 creator A5015585176 @default.
• W2113686775 creator A5022702941 @default.
• W2113686775 creator A5027170448 @default.
• W2113686775 creator A5031325368 @default.
• W2113686775 creator A5040391372 @default.
• W2113686775 creator A5042529049 @default.
• W2113686775 creator A5045494904 @default.
• W2113686775 creator A5048695091 @default.
• W2113686775 creator A5048844031 @default.
• W2113686775 creator A5049314303 @default.
• W2113686775 creator A5053848207 @default.
• W2113686775 creator A5055943724 @default.
• W2113686775 creator A5070720153 @default.
• W2113686775 creator A5081543892 @default.
• W2113686775 creator A5088566246 @default.
• W2113686775 creator A5089509810 @default.
• W2113686775 date "2013-03-14" @default.
• W2113686775 modified "2023-10-16" @default.
• W2113686775 title "Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study" @default.
• W2113686775 cites W1967060514 @default.
• W2113686775 cites W1971837077 @default.
• W2113686775 cites W1993016882 @default.
• W2113686775 cites W1994193851 @default.
• W2113686775 cites W2010348162 @default.
• W2113686775 cites W2012222876 @default.
• W2113686775 cites W2023164440 @default.
• W2113686775 cites W2024760455 @default.
• W2113686775 cites W2046623913 @default.
• W2113686775 cites W2072334819 @default.
• W2113686775 cites W2079586464 @default.
• W2113686775 cites W2086261536 @default.
• W2113686775 cites W2096415778 @default.
• W2113686775 cites W2097373408 @default.
• W2113686775 cites W2101517420 @default.
• W2113686775 cites W2109746877 @default.
• W2113686775 cites W2114639921 @default.
• W2113686775 cites W2137758263 @default.
• W2113686775 cites W2139248078 @default.
• W2113686775 cites W2139877124 @default.
• W2113686775 cites W2140765540 @default.
• W2113686775 cites W2153935627 @default.
• W2113686775 cites W2154493372 @default.
• W2113686775 cites W2157535532 @default.
• W2113686775 cites W2158642531 @default.
• W2113686775 cites W2168865951 @default.
• W2113686775 cites W2597772206 @default.
• W2113686775 cites W2599724890 @default.
• W2113686775 doi "https://doi.org/10.1158/1078-0432.ccr-12-3041" @default.
• W2113686775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3609423" @default.
• W2113686775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23362324" @default.
• W2113686775 hasPublicationYear "2013" @default.
• W2113686775 type Work @default.
• W2113686775 sameAs 2113686775 @default.
• W2113686775 citedByCount "65" @default.
• W2113686775 countsByYear W21136867752013 @default.
• W2113686775 countsByYear W21136867752014 @default.
• W2113686775 countsByYear W21136867752015 @default.
• W2113686775 countsByYear W21136867752016 @default.
• W2113686775 countsByYear W21136867752017 @default.
• W2113686775 countsByYear W21136867752018 @default.
• W2113686775 countsByYear W21136867752019 @default.
• W2113686775 countsByYear W21136867752020 @default.
• W2113686775 countsByYear W21136867752021 @default.
• W2113686775 countsByYear W21136867752022 @default.
• W2113686775 countsByYear W21136867752023 @default.
• W2113686775 crossrefType "journal-article" @default.
• W2113686775 hasAuthorship W2113686775A5008468404 @default.
• W2113686775 hasAuthorship W2113686775A5013091949 @default.
• W2113686775 hasAuthorship W2113686775A5015585176 @default.
• W2113686775 hasAuthorship W2113686775A5022702941 @default.
• W2113686775 hasAuthorship W2113686775A5027170448 @default.
• W2113686775 hasAuthorship W2113686775A5031325368 @default.
• W2113686775 hasAuthorship W2113686775A5040391372 @default.
• W2113686775 hasAuthorship W2113686775A5042529049 @default.
• W2113686775 hasAuthorship W2113686775A5045494904 @default.
• W2113686775 hasAuthorship W2113686775A5048695091 @default.
• W2113686775 hasAuthorship W2113686775A5048844031 @default.
• W2113686775 hasAuthorship W2113686775A5049314303 @default.
• W2113686775 hasAuthorship W2113686775A5053848207 @default.
• W2113686775 hasAuthorship W2113686775A5055943724 @default.
• W2113686775 hasAuthorship W2113686775A5070720153 @default.
• W2113686775 hasAuthorship W2113686775A5081543892 @default.
• W2113686775 hasAuthorship W2113686775A5088566246 @default.
• W2113686775 hasAuthorship W2113686775A5089509810 @default.
• W2113686775 hasBestOaLocation W21136867751 @default.
• W2113686775 hasConcept C112705442 @default.
• W2113686775 hasConcept C126322002 @default.
• W2113686775 hasConcept C141341695 @default.
• W2113686775 hasConcept C143998085 @default.
• W2113686775 hasConcept C203092338 @default.
• W2113686775 hasConcept C2778019345 @default.
• W2113686775 hasConcept C2778695046 @default.
• W2113686775 hasConcept C2992208098 @default.
• W2113686775 hasConcept C535046627 @default.

• next